AstraZeneca的试验发现 Ceralasertib 加上 Imfinzi 没有延长前期治疗后 肺癌患者的存活期。 AstraZeneca's trial found ceralasertib plus Imfinzi didn't extend survival in advanced lung cancer patients after prior treatment.

AstraZeneca第三阶段对ceralasertib与Imfinzi结合进行的Ceralasertib试验没有改善前期治疗后进展的高级非小型细胞肺癌患者的总体存活率。 AstraZeneca's Phase III trial of ceralasertib combined with Imfinzi did not improve overall survival in patients with advanced non-small cell lung cancer who had progressed after prior treatments. 这项研究涉及20个国家的594名病人,但发现与标准护理相比没有重大益处,尽管综合治疗效果良好,没有出现新的安全问题。 The study, involving 594 patients across 20 countries, found no significant benefit compared to standard care, though the combination was well-tolerated with no new safety issues. Ceralasertib将DNA修复蛋白质作为目标,以促进免疫疗法,但结果没有达到预期。 Ceralasertib targets a DNA repair protein to boost immunotherapy, but results fell short of expectations. 尽管遭受挫折,AstraZeneca说,它仍然致力于通过正在进行的研究推进肺癌治疗。 Despite the setback, AstraZeneca said it remains committed to advancing lung cancer treatments through ongoing research.